The Montreux Healthcare Fund has completed the purchase of Chester Healthcare Limited (CHL), a Healthcare agency staffing business with coverage spanning the North West and South West of England.

The acquisition will allow Active Assistance to employ a more flexible staffing model across the business and CHL’s global reach will provide some mitigation of post-Brexit staffing risk. Adding an additional c.£1m EBITDA to Active Assistance, with broader scope to expand the businesses further, CHL will provide a platform with which to build a business that can serve the whole group. This is a strategic purchase that will allow for more flexible staffing throughout the Active group, dramatically reducing agency usage and providing considerable upside for Active Assistance. There are a large amount of synergy savings and value add opportunities by bolting on Chester Healthcare and it opens up an avenue of recruiting highly qualified nurses from around the globe.

Oliver Harris, CEO, Montreux Capital Management stated: “The purchase of Chester Healthcare Limited is a good strategic acquisition for Active Assistance as it will allow the business to have access to a flexible staffing pool at much lower cost than most of its competitors. We feel that the acquisition will help with the staffing headwinds which might occur post-Brexit and that, more importantly, the integration of this business will increase Active Assistance’s appeal upon exit.”

Find Us

Thameside House
Hurst Road
East Molesey
KT8 9AY

T: + 44 (0) 1932 860 140
E: info@montreuxcm.com

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together “the Sponsors,” or “Sponsor”) do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.

ACCEPT